Japanese Patent Office to Grant SUDA’s Anagrelide Cancer Patent

May 20, 2020 12:35 PM AEST
Team Kalkine

Australia-based oro-mucosal drug delivery company, SUDA Pharmaceuticals (ASX:SUD) notified in its latest update that the Japanese Patent Office has accepted its patent application for Anagrelide. Consequently, the Anagrelide Cancer Patent will proceed to grant.

Below are the key details of the patent:

Application No.: 2017-534600
Title: Use of Anagrelide for Treating Cancer
Expiry date: December 2035

Anagrelide is an EMA and FDA approved drug to treat blood disorders and recent research has continued to support the rationale for its use in treating cancer. Notably, SUDA is the only firm across the world holding patents covering the use of anagrelide in treating or preventing metastatic disease in the bone or lung.

Post the update, SUD stock surged by ~10.3 per cent, trading at $0.043 as at 12:15 PM AEST on 20 May 2020.

Disclaimer

The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.